COR Therapeutics, Inc. Confirms Prior Guidance for Profitable Fourth Quarter of 2001 and for Sales of INTEGRILIN in 2001.Business & Health Editors SOUTH SAN FRANCISCO South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , Calif.--(BW HealthWire)--Jan. 7, 2002 COR Updates 2001 INTEGRILIN(R) Sales Estimates COR Therapeutics, Inc. (Nasdaq: CORR CORR Used on the consolidated tape to indicate a correction in a reported transaction : CORR.LAST.GY 50 WAS 51. ) today confirmed prior guidance of a profit for the fourth quarter and for the full year of 2001, based on unaudited financial data. COR also said that year-end 2001 sales of INTEGRILIN(R) (eptifibatide) Injection, as reported to COR by its worldwide partner for INTEGRILIN, Schering-Plough Corporation, would be approximately $208 million in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. and approximately $230 million on a worldwide basis, at the high end of the range of $225 - $230 million worldwide included in guidance previously provided. COR noted that this represents a 34% increase over worldwide sales reported for 2000. COR Therapeutics, Inc. is dedicated to the discovery, development, and commercialization of novel pharmaceutical products for the treatment and prevention of severe cardiovascular diseases Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease . In addition to the historical information contained herein, this press release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from the anticipated results discussed in such forward-looking statements, due to factors related to the commercialization of INTEGRILIN and other factors discussed in the Company's SEC reports, including, but not limited to, the Company's Quarterly Report on Form 10-Q Form 10-Q See 10-Q. for the quarter ended September 30, 2001, and Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2000. Forward-looking statements are based on current expectations and the Company does not intend to update such information to reflect later events or developments. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion